Maine Immunization Program Update - May 2023

Maine Immunization Program

Update

May 2023

OBH Logo


calendar

IMPORTANT: Upcoming Due Dates for Program Requirements

As we approach summer, we would like to remind MIP-enrolled providers of upcoming program requirements. Providers will be required to complete the following requirements by/starting on July 1, 2023:
  • DUE JULY 1: Provider Agreement
    • UPDATED agreement will be available in early JUNE - a communication will be sent to providers to let them know when it is accessible through ImmPact. 
  • DUE JULY 1: Data Logger Calibration Certificate
    • MIP-enrolled sites must also submit a copy of their calibration
      certificates for all primary and backup data loggers that are used to monitor the temperatures in units that store MIP vaccine. 

For ALL primary and secondary vaccine coordinators:

  • DUE: JULY 1 - OCTOBER 1: Vaccines for Children annual educational training and post-test. 
    • Any trainings completed prior to July 1 will not count toward satisfying the requirement in the upcoming fiscal year (July 1, 2023 – June 30, 2024). Any new providers who were hired or inherited a primary or secondary coordinator position prior to July 1, 2023, will not need to complete the training again until the next cooperative agreement period (July 1, 2024). All other providers must complete the training and post-test by October 1 of each cooperative agreement period.
    • The combined trainings and post-tests are located on the following webpage: Annual Education Requirement |Immunization | MeCDC | Maine DHHS. Failure to complete this education requirement will impact your ability to order vaccines within ImmPact.

For ALL ImmPact Users:

  • DUE JULY 1: MIP ImmPact User Agreement
    • MIP requires all users to provide a signed ImmPact user
      agreement in order to continue to have access to the ImmPact system. All accounts without an updated user agreement by July 1st will be terminated until a completed form has been submitted.

hep awareness

May is Hepatitis Awareness Month

May is Hepatitis Awareness Month across the United States, and May 19 marks National Hepatitis Testing Day. Help shed light on the burden of viral hepatitis and encourage testing and vaccination according to CDC recommendations. Key facts:

  • Several viruses cause hepatitis. The most common types are hepatitis A, hepatitis B, and hepatitis C.
  • Chronic hepatitis B and hepatitis C are the leading causes of liver cancer in the United States
  • Both hepatitis A and hepatitis B are preventable with safe and effective vaccines

Vaccine Recommendations:

  • CDC recommends all adults through age 59 and adults aged 60 or older with risk factors get vaccinated against hepatitis A and hepatitis B. If you are age 60 or older and do not have risk factors, you may choose to get vaccinated.
  • About 66% of people with hepatitis B are unaware of their infection and about 40% of people living with hepatitis C do not know they are infected.
  • CDC recommends all adults get tested for hepatitis B and hepatitis C at least once in their lifetime and pregnant women get tested during each pregnancy. Getting tested is the only way to know if you have hepatitis B or hepatitis.

Resources:

Hepatitis Awareness Month | CDC

Hepatitis A Vaccine Information (immunize.org)

Hepatitis B Vaccine Information (immunize.org)


What’s New & Updated for COVID-19

covid 19

For people who are not moderately or severely immunocompromised: 

For people who are moderately or severely immunocompromised: 

  • At the time of initial vaccination, people ages 6 months and older are recommended to receive 3 bivalent mRNA doses. 
  • People ages 6 months and older who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on age and vaccine product.
  • People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1 or more additional bivalent mRNA doses.

Important Reminders:

  • Pfizer and Moderna’s monovalent COVID-19 vaccines are no longer authorized for use and have been replaced by their bivalent products.  
  • Janssen/J&J COVID-19 vaccine is no longer available in the U.S.  
  • People 12 years and older who are unable or choose not to get an updated Pfizer-BioNTech or Moderna COVID-19 vaccine may consider receiving the Novavax COVID-19 vaccine.  

Resources:

Clinical Guidance for COVID-19 Vaccination | CDC

COVID-19 Vaccine—Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older (cdc.gov)

COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC

UPDATED: Interim Clinical Considerations for Use of COVID-19 Vaccines (govdelivery.com)

Moderna Bivalent COVID-19 Vaccine


Call for Nominations: 2023 Immunization Champion Award

IAC

2023 will mark AIM’s second year running the Immunization Champion Award program,
previously known as the CDC Childhood Immunization Champion Award. The Immunization
Champion Award recognizes individuals who are doing an exemplary job or going above and
beyond to promote or foster immunizations in their communities, for both children and adults.

Nominations for Maine will close at 5pm on Wednesday, May 31, 2023. Please share this information with your networks.

Completed nomination forms can be sent via email to camille.erickson@maine.gov or faxed to
207-287-8127 attention Camille Erickson.

2023 AIM Champion Award Program Nomination Packet 

Notification to providers 


Combination Vaccines & Invalid Doses Webinar - May 24, 2023 @ 12 PM

MIP is pleased to host an educational lunch and learn on Wednesday, May 24th, 2023 @ 12 PM. This webinar will address combination vaccines and why vaccines may show up as invalid in ImmPact. There will be a presenter from MIP’s Quality Improvement team. Please join us for this opportunity.

Join Zoom Meeting – May 24, 2023

https://mainestate.zoom.us/j/86400912356?pwd=N3d5ekxGQ3kxNVUwdkV4UWc2RGtzUT09

Meeting ID: 864 0091 2356

Passcode: 10817265


Data Logger FAQs

dl

HOW DO I START THE LOGTAG TRED30?

The LogTag data loggers have a start/clear/stop button that needs to be pressed firmly with thumb or finger to make the screen display “starting”. This will blink several times until it “double blinks”. When “starting” blinks twice rapidly instead of once, take your finger/thumb off the button. The logger display should produce a temperature; this is how you know it is started.

WHY DOES THE SCREEN SAY -199.99?

This number indicates the LogTag took a reading with the probe not inserted. The display will change when the next sample is taken and the probe is inserted properly.

THE DISPLAY ISN'T READING A TEMP AND SAYS STOPPED.

This indicates that the logTag either ran out of memory and stopped recording, or was stopped by holding the start/clear/stop button. To restart the readings, insert the LogTag into the docking station and run it through the software again.

HOW DO I CHECK THE MIN/MAX?

The top button on the front of the logger says “review/mark”; press this button to review the min/max for the previous days. The numbered box below the temperature indicates how many days prior to the current reading that min/max was taken.

WHY IS THERE AN "X" OVER THE BATTERY SYMBOL?

The “X” over the battery symbol indicates a dead battery.

HOW DO I CHANGE THE BATTERY?

There is a white plastic square that is adhered onto the back of the LogTag that may be covered by a calibration sticker. If you peel the calibration sticker up slightly from the bottom left corner you will see a notch that you can slide a fingernail or razor underneath to pry up the white square. Underneath the square is a round plug that you must twist (best to use a spare battery or quarter) to the left to remove and reveal the CR2032 battery. This can be removed with a small standard (flat) screwdriver.

For more information about LogTag data loggers, please visit: 

Quick Start Guide

Support | Control Solutions (vfcdataloggers.com) - Find helpful information and troubleshooting support for your device.

Software Downloads

Requesting Calibration

Contact Control Solutions


MMR and Varicella Merck Products May Be Administered IM or Subcutaneous

IMSM

The Food and Drug Administration (FDA) approved the intramuscular (IM) administration of Merck’s M-M-R III, VARIVAX, and ProQuad. IM administration is an option in addition to subcutaneous administration for these Merck products. No recommendation is needed from the Advisory Committee on Immunization Practices and providers can start administering these vaccines at this time. 

Please note that the subcutaneous route remains the only approved route for Priorix, MMR vaccine from GSK.


MIP Listserv

If you know someone who is not receiving MIP communications and would like to, please have them sign up on our website in the red outlined area shown in the picture below or email us at: ImmunizeME.DHHS@maine.gov to be added. 

tempsnip